Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexicon Pharmaceuticals (LXRX) Equity Average (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Equity Average for 5 consecutive years, with $113.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 29.82% to $113.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $113.8 million, a 29.82% decrease, with the full-year FY2025 number at $126.7 million, up 6.04% from a year prior.
  • Equity Average was $113.8 million for Q4 2025 at Lexicon Pharmaceuticals, down from $124.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $264.4 million in Q2 2024 to a low of $113.8 million in Q4 2025.
  • A 3-year average of $159.4 million and a median of $149.7 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 92.72% in 2024, then tumbled 52.26% in 2025.
  • Lexicon Pharmaceuticals' Equity Average stood at $116.3 million in 2023, then surged by 39.48% to $162.2 million in 2024, then fell by 29.82% to $113.8 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Equity Average are $113.8 million (Q4 2025), $124.8 million (Q3 2025), and $126.2 million (Q2 2025).